Navigation Links
Denosumab delays development of prostate cancer bone metastasis
Date:11/15/2011

An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The study, receiving Online First publication in The Lancet, is the first to successfully reduce bone metastasis in such patients and supports the importance of targeting the bone microenvironment to prevent prostate tumor spread.

"Prostate cancer patients who develop bone metastases usually have poor outcomes, so preventing the development of metastasis has been a major unmet clinical need," says Matthew Smith, MD, PhD, of the MGH Cancer Center, lead and corresponding author of the Lancet paper. "This first demonstration of a treatment that can meet that goal is a significant accomplishment that should lead to better treatment strategies."

Bone is the most common site in some patients the only site for the development of prostate cancer metastases, which can lead to pain, fractures and the need for surgery or radiation therapy. Almost all men who die from prostate cancer have bone metastasis. Previous research has suggested that metastatic development involves interactions between tumor-secreted growth factors and the normal process by which bone tissue is broken down and rebuilt. Animal studies have indicated that inhibiting osteoclasts cells that cause the resorption of bone can prevent metastasis and that expression on cancer cells of a signalling protein called RANKL, which activates osteoclasts, may prepare the bone microenvironment for tumor spread.

Denosumab is a monoclonal antibody against RANKL and is FDA approved for two uses treatment of osteoporosis and prevention of fractures in patients with bone metastases from solid tumors. Denosumab is marketed by Amgen which supported the current study under the brand names Prolia for osteoporosis treatment and Xgeva for cancer treatment. The current study enrolled 1,432 participants at 319 centers in 30 countries all prostate cancer patients whose tumors had stopped responding to androgen-deprivation therapy and were metastasis-free, although rising PSA levels indicated they were at risk for metastasis.

Participants were randomly assigned to receive injections of either denosumab or a placebo every four weeks. During the two-year study period, patients were examined including a bone scan every four months, and X-ray skeletal surveys performed annually. If a bone scan indicated the presence of metastasis, it was confirmed with either X-ray, CT scan or MRI. After that confirmation, study treatment was discontinued, since other therapies are approved to treat metastatic prostate cancer.

Study results indicated that denosumab treatment increased bone-metastasis-free survival defined as the time to either the first metastasis or death from any cause by an average of more than four months, extended the time to first metastasis and delayed symptoms of metastasis. Biochemical markers indicated that denosumab treatment did reduce bone turnover. While there was no survival difference between the two study groups, the authors note that that fact that denosumab was discontinued when the first metastasis was diagnosed makes judging the drug's effects on survival difficult.


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Denosumab delayed time to first skeletal-related side effect
2. Toronto researchers find first physical evidence bilingualism delays onset of Alzheimers symptoms
3. Folic Acid in Pregnancy May Prevent Kids Language Delays
4. New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients
5. Phase II study shows new cancer drug combination significantly delays breast cancer progression
6. Emergency treatment for heart attack improving but delays still occur
7. ADHD Drug Delays Puberty in Male Monkeys, Study Finds
8. One-Third of Severe Heart Attack Patients Have Treatment Delays
9. Many Pediatricians Arent Testing Tots for Developmental Delays
10. Hospital Delays Tied to Racial Divide in Heart Attack Care
11. Delays in Hospital Transfers for Heart Attack Patients May Raise Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: